← All trials
NCT03117608
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2017
- Primary completion
- Aug 24, 2022
- Completion date
- Feb 24, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 118
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Lipogems International spaLead sponsor
- Lipogems International spaReponsible party - principal investigator
- Lipogems International spaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.